Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
 from The Nasdaq Stock Market - EconoTimes)
NEW YORK, April 18, 2018 -- The Nasdaq Stock Market announced today that it will delist the common stock of Rex Energy Corporation. Rex Energy Corporation’s stock was suspended on April 12, 2018 and has not traded on Nasdaq since that time.
Nasdaq also announced that it will delist the common stock of PhaseRx, Inc. PhaseRx, Inc.’s stock was suspended on February 05, 2018 and has not traded on Nasdaq since that time.
Nasdaq also announced that it will delist the common stock of Stanley Furniture Company, Inc. Stanley Furniture Company, Inc.’s stock was suspended on March 15, 2018 and has not traded on Nasdaq since that time.
Finally, Nasdaq announced that it will delist the warrant of Innovate Biopharmaceuticals, Inc. Innovate Biopharmaceuticals, Inc.’s warrant was suspended on March 05, 2018 and has not traded on Nasdaq since that time.
Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delisting for each of these companies. The delistings become effective ten days after the Form 25 is filed. For news and additional information about the companies, including the basis for the delistings and whether the companies’ securities are trading on another venue, please review the companies’ public filings or contact the company directly.
For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com. Nasdaq’s rules governing the delisting of securities can be found in the Nasdaq Rule 5800 Series, available on the Nasdaq Web site: http://www.cchwallstreet.com/NasdaqTools/bookmark.asp?id=nasdaq-rule_5800&manual=/nasdaq/main/nasdaq-equityrules/.
NDAQO
